Mucosal melanoma (MM) is an aggressive and rare subtype of melanoma, and it is associated with poor prognosis. Surgical resection remains the mainstay of the treatment for localized disease, and different from cutaneous melanoma, the impact of adjuvant therapy has not been clearly established. We retrospectively analyzed patients with surgically resected MM from the MD Anderson Cancer Center melanoma database from January 2000 to December 2019. The univariate log-rank test and multivariate Cox regression model were used to analyze the impact of adjuvant therapy on overall survival (OS) and relapse-free survival. A total of 246 patients with localized or locally advanced MM who underwent surgical resection were included. The median OS for all patients was 4.8 years [95% confidence interval (CI), 3.6-6], with median OS for the 125 patients who received adjuvant systemic therapy was 5.7 years (95% CI, 4.0-10.2) and 4.0 years (95% CI, 2.8-6.6) for the 121 patients who had only surgery or surgery plus radiation in the subanalysis, chemotherapy was associated with a longer OS (7.3 years; 95% CI, 4.4-NA) compared to immunotherapy (5.5 years; 95% CI, 2.8-NA). Cox regression analysis demonstrated lymph node involvement, Breslow thickness, and use of adjuvant systemic therapy were considered independent factors for OS. Adjuvant systemic therapy was associated with a significant survival benefit in patients with resected MM (HR 0.53; 95% CI, 0.34-0.82; P = 0.004). However, due to the retrospective nature of the study, prospective clinical trials are warranted to determine the optimal adjuvant treatment strategy for this patient population.

Endometrial carcinoma (EC) is a common gynecological malignancy whose incidence has been increasing globally. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) has been implicated in several cancers, but its clinicopathological and prognostic significance in EC remains unclear. A total of 66 EC patients who underwent surgical treatment between September 2017 and September 2018 were included. Paired tumor and adjacent normal tissues (>3cm from the tumor margin) were analyzed by immunohistochemistry using a validated anti-ROR1 antibody. ROR1 expression was semi-quantitatively scored based on staining intensity and the percentage of positive cells, with scores ≥6 indicating high expression. Associations between ROR1 expression and clinicopathological features were evaluated using χ2 tests and logistic regression. Univariate and multivariate logistic regression models identified independent predictors of high ROR1 expression, and model fit was assessed using the Hosmer-Lemeshow test and ROC analysis. Kaplan-Meier and Cox proportional hazards models were used to assess the prognostic impact of ROR1 expression on overall survival (OS), with subgroup analyses stratified by clinical stage and histological type. ROR1 was highly expressed in 65.15% (43/66) of EC tissues compared with 22.73% (15/66) of adjacent normal tissues (p<0.05). The mean number of ROR1-positive cells was significantly greater in high-expression tumors (86.15±9.79) than in normal endometrial tissue (3.13±1.25) or low-expression tumors (6.08±3.37) (p<0.05). High ROR1 expression was significantly associated with advanced clinical stage (III-IV), Type II histology, lymph node metastasis, and poor prognosis (all p<0.05). Multivariate logistic regression confirmed that ROR1 overexpression was independently associated with advanced stage (OR=11.59, p=0.004), Type II histology (OR=4.68, p=0.031), and poor prognosis (OR=5.68, p=0.036). Kaplan-Meier analysis demonstrated that patients with high ROR1 expression had a shorter median OS (46vs. 59 months, p<0.001). Subgroup analyses revealed that the prognostic value of ROR1 was most evident in Stage I-II and Type I EC, where high expression remained an independent predictor of poor survival after multivariate adjustment (HR=4.07, 95% CI: 1.71-9.66, p=0.0015). ROR1 is markedly overexpressed in endometrial carcinoma and independently associated with advanced stage, Type II histology, and adverse prognosis. High ROR1 expression predicts shorter overall survival, particularly in early-stage and Type I EC, supporting its potential as a prognostic biomarker. Given the retrospective single-center design, limited sample size, and absence of molecular validation, further multicenter and mechanistic studies are warranted to confirm these findings.

Objective: To describe the epidemiology, survival rate, and prognostic factors of mucosal-associated lymphoid tissue (MALT) lymphoma. Patients and Methods: This investigation utilized the Thai Lymphoma Study Group (TLSG) registry to gather data on patients diagnosed with MALT lymphoma. The analysis included demographic details, therapeutic interventions, and survival statistics. Results: The TLSG registry prospectively included 8404 patients with lymphoma. Among them, marginal-zone lymphoma (MZL) was the second most common subtype, with 670 histologically confirmed cases, accounting for 8.0% of the total cohort. An analysis of the MZL subtypes showed that MALT lymphoma was the most common, accounting for 77.8% of the diagnoses. This was followed by nodal MZL at 17.5% and splenic MZL at 7.7%. The distribution of primary disease sites indicated that the ocular adnexa (49.2%), stomach (12.9%), and sinonasal region (12.5%) were the three most common locations. Three variables were found to be statistically significant predictors of survival in the multivariate analysis: ECOG performance status &gt; 2, age exceeding 65 years, and involvement of more than two extranodal organs. These identified prognostic factors were further assessed for their effect on overall survival (OS) and progression-free survival (PFS). A risk classification was established: the low-risk group comprised patients with zero identified risk factors, whereas the high-risk group included patients who had any of the specified risk factors. A comparison of five-year survival rates showed significantly more favorable outcomes for low-risk patients who had a PFS of 83.3% (vs. 66.1%, p = 0.028) and an OS of 97.8% (vs. 76.7%, p &lt; 0.001) compared to the high-risk group. Conclusions: In this cohort, where MZL was the second most common lymphoma and MALT lymphoma was the predominant subtype, our analysis revealed that patients with no risk factors experienced statistically significant improvements in both PFS and OS.

Background/Objectives: SNMM is a rare and aggressive malignancy with a poor prognosis. The current staging systems fail to adequately stratify patient risk. This study aimed to evaluate the prognostic impact of tumor location and extension on overall survival (OS) in SNMM. Methods: A systematic literature search of Medline, Web of Science, and Embase was performed to identify studies assessing the prognostic significance of tumor location and extension. Study quality was evaluated using the Quality in Prognosis Studies (QUIPS-2) tool. Meta-analyses were conducted to calculate pooled hazard ratios (HRs) with 95% confidence intervals (CIs). Eligible studies included primary SNMM reporting tumor location/extension and survival; observational designs (case series ≥ 5 patients) were eligible with no language restrictions. Searches covered MEDLINE, Web of Science, and Embase and were last updated on 10 Jan 2025; reference lists were also screened. Results: Thirty-four studies were included in the systematic review, of which ten met criteria for meta-analysis. Tumors located in the paranasal sinuses (HR = 2.89, 95% CI: 1.63–5.14) and those with orbital involvement (HR = 1.92, 95% CI: 1.34–2.73) were associated with significantly poorer OS. Maxillary and ethmoid sinus involvement showed no statistically significant difference compared with nasal cavity tumors. Conclusions: Tumor location and extension are significant prognostic indicators in SNMM. Patients with paranasal sinus tumors or orbital invasion have worse outcomes, supporting inclusion of these factors in future staging systems for better clinical decision-making. Limitations include the observational nature of the evidence, heterogeneity across definitions and analyses, and underpowered publication-bias tests; certainty of evidence was not formally graded.

The primary aim of this study was to evaluate the impact of cyclooxygenase-2 (COX-2) expression on overall survival (OS), local recurrence-free survival (LRFS), and regional recurrence-free survival (RRFS) in patients diagnosed with advanced oral squamous cell carcinoma (AOSCC). COX-2 expression levels were assessed in 191 cases of AOSCC and 50 cases of normal mucosa using immunohistochemistry (IHC). Comparisons were made between COX-2 expression in AOSCC and normal mucosal tissues, as well as its influence on OS, LRFS, and RRFS. The Cancer Genome Atlas (TCGA)- Head and Neck Squamous Cell Carcinoma (HNSC) database was utilized for validation. In this cohort of 191 patients with AOSCC followed for 1-145 months (median: 68.3 months), AOSCC Patients exhibited significantly higher COX-2 expression compared to normal oral mucosa tissues. Consistent result was obtained from analysis of the AOSCC subgroup from TCGA HNSC cohort. In the subset of AOSCC patients filtered from the TCGA-HNSC database, COX-2 mRNA expression showed no statistically significant association with survival. However, In our cohort of AOSCC patients from IHC analysis, COX-2 expression emerged as an independent prognostic factor for OS, LRFS, and RRFS. Positive COX-2 expression was associated with a markedly increased risk of recurrence and diminished survival outcomes. COX-2 is overexpressed in AOSCC and appears to be a potential adverse prognostic factor in our cohort. As a biomarker, COX-2 may offer valuable prognostic insights for AOSCC.

BACKGROUNDChemotherapy is an essential treatment for colorectal cancer (CRC) patients after surgery, but many patients do not benefit from chemotherapy because tumour heterogeneity results in varied responses.AIMTo study the effectiveness of in vitro chemosensitivity tests adenosine triphosphate-based tumour chemotherapy sensitivity test (ATP-TCA) for tailoring postoperative chemotherapy regimens for patients with CRC.METHODSBetween January 2015 to December 2021, a total of 1549 CRC patients underwent surgery and in vitro chemosensitivity testing using ATP-TCA. A subset of 405 patients who met the survival assessment criteria were followed to collect data on overall survival (OS) and disease-free survival (DFS). Cox regression analysis revealed independent prognostic factors that affect OS and DFS for those receiving oxaliplatin (L-OPH) and fluoropyrimidine-based regimens, aiding in the development of clinical predictive models. The relationships between the ATP-TCA results and clinical outcomes were analysed using the Kaplan-Meier method.RESULTSTumour heterogeneity and resistance to multiple drugs were observed in 1549 patients. The sensitivity to 5-fluorouracil (5-FU) combined with L-OPH was tested among 1474 of these patients, yielding a sensitivity rate of 11.9%. ATP-TCA results were identified as an independent prognostic factor for DFS [P = 0.002, hazard ratio (95% confidence interval): 4.98 (1.81-13.72)] in patients with resectable CRC. Compared with drug-resistant patients, sensitive CRC patients treated with 5-FU and L-OPH had significantly prolonged DFS (P = 0.027). Further Kaplan-Meier analysis indicated that ATP-TCA sensitivity was significantly associated with improved OS (P = 0.048) and DFS (P = 0.003) in patients with stage III CRC.CONCLUSIONThe response of CRC patients to the combination regimen of 5-FU and L-OPH is heterogeneous. This study confirmed that the ATP-TCA is a valuable tool for predicting clinical outcomes, such as DFS, in patients with resectable CRC receiving chemotherapy. Although further validation with multicentre data is still necessary, these findings support that the ATP-TCA may function as a guiding tool for personalized chemotherapy administration, thereby optimizing treatment opportunities for patients.

BackgroundLack of human epidermal growth factor receptor 2 (HER2) expression limits targeted treatments for triple-negative breast cancer (TNBC). HER2 status changes after neoadjuvant chemotherapy (NAC) have been reported, but their impact on survival in Peruvian TNBC patients remains unexplored. Here, we aimed to assess HER2 status before and after NAC and its association with clinical characteristics, treatment response, and survival outcomes.MethodsOur analysis included clinicopathological data from 159 TNBC patients diagnosed between 2015 and 2019 at the Instituto Nacional de Enfermedades Neoplásicas (Lima, Peru) who received NAC. Logistic regression was used to assess the association between HER2 status at diagnosis and pathological complete response (pCR). Cohen's Kappa analysis evaluated the agreement between pre- and post-NAC HER2 status, while Kaplan–Meier analysis estimated the impact of HER2 changes on overall survival (OS) and disease-free survival (DFS)ResultsAmong TNBC patients, 40.3% were HER2-low at diagnosis and 14.9% achieved pCR. Pretherapeutic HER2 status was not associated with pCR (OR = 1.4, 95% CI = 0.55–3.61, and p=0.5). HER2 status remained unchanged in 62.8% of HER2-zero and 75.9% of HER2-low patients post-NAC, showing moderate concordance (Cohen's kappa = 0.3418, p < 0.001). No significant OS improvements were observed in patients with HER2 transitions: HER2-zero/HER2-low (HR = 0.52, 95% CI = 0.22–1.24, and p=0.14), HER2-low/HER2-zero (HR = 0.9, 95% CI = 0.34–2.40, and p=0.8), or HER2-low/HER2-low (HR = 0.71, 95% CI = 0.34–1.49, and p=0.4) compared with HER2-zero/HER2-zero. Similar findings were reported for DFS.ConclusionThese findings suggest that HER2 status conversion may not be prognostic for patients with TNBC treated with neoadjuvant therapy.

Abstract Molecular subgrouping (MS) has stratified outcomes in medulloblastoma, while the extent of resection (EOR) remains the standard of care. When gross total resection (GTR) is not possible due to the tumor’s invasive nature or risk of neurological deficits, MS can guide decisions on adjuvant therapy versus redo surgery. Although radiomics can suggest possible molecular subgroups, intraoperative pathological testing has not yet evolved to confirm subgroups for surgical decisions. We retrospectively analyzed single-center data on medulloblastomas with MS to assess the impact of EOR on overall survival (OS) and progression-free survival (PFS) across various subgroups. Out of 593 patients, 296 were included in the final analysis. When EOR was evaluated for the entire cohort, radical resection was associated with better OS, but a similar benefit was not observed with PFS. Kaplan-Meier curves showed better 5-year OS and PFS in the WNT subgroup compared to others. In subgroup analysis, EOR did not alter OS or PFS in WNT, SHH, and group 4. In group 3, OS was unaffected, but PFS was significantly better in the GTR+NTR group compared to STR (p=0.039). Multivariate analysis revealed that EOR did not influence OS or PFS in any subgroup. In group 3, EOR impacts OS and PFS, while factors like metastasis at presentation and incomplete adjuvant treatment also affect outcomes. Despite challenges in intraoperative MS analysis, maximal and safe surgical resection should be pursued, as chasing residual tumors does not alter outcomes in medulloblastomas except in group 3.

Abstract BACKGROUND Varian HyperArcTM (HA) is a novel treatment innovation for Stereotactic Radiosurgery (SRS), helpful in improving treatment efficiencies and overall patient experience. MATERIAL AND METHODS This is a retrospective study of 228 patients diagnosed with brain metastases (mets) from solid tumours, who have received SRS at our centre using the HA treatment platform between 2022-2024. The aim of the study was to analyse impact of various clinical factors (primary diagnosis, number of metastases, Planning treatment volume (PTV) and metachronous or synchronous presentation) on overall survival (OS). The OS was calculated from the date of SRS treatment. Statistical analyses were conducted using IBM SPSS Statistics for Windows, version 29.0.2.0. RESULTS The median OS for the entire cohort was 15 months (CI 12.19-17.80). Primary histology has a significant impact on survival with best survival in patient with breast cancer and worst with upper gastrointestinal cancers (22 months vs 3 months respectively) (p=-0.01, log rank test). Number of mets did not significantly affected OS, the median OS was 18 months (CI 0.41-35.58) for ≤5 metastases and 15 months (CI 12.058-17.492) for &amp;gt;5 metastases (p=0.781, log rank test). We also noticed a significant impact of PTV on OS. The median OS was 9 months (CI 5.580-12.420) in patients who had a PTV volume&amp;gt;10cm3 in comparison to 19 months (CI 14.88-23.11) for patients with PTV volume of &amp;lt;10cm3 (p=0.01, log rank test). There was no statistically significant impact of synchronous or metachronous presentation noted on OS. (median OS was 18 months (CI 9.60-26.39) and 15 months (CI 11.73-18.26) respectively (p=0.46, log rank test). CONCLUSION In our experience primary cancer diagnosis significantly affects the OS in the brain metastases patients. Our results also emphasized the importance of careful patient selection and to prioritise smaller volumes than the number of metastasis when treating with SRS.

Abstract INTRODUCTION Despite the recognized prognostic value of isocitrate dehydrogenase (IDH) mutations in gliomas, real-world survival data from low- and middle-income countries (LMICs), particularly in Latin America, are scarce. This study aimed to evaluate the prognostic impact of IDH mutation status on overall survival (OS) in a national cohort from Panama. MATERIALS AND METHODS We retrospectively analyzed 196 glioma patients diagnosed between 2018 and 2023 at the National Oncology Institute of Panama. Tumor histology and grade were classified according to the 2021 WHO Classification. IDH mutation status was assessed via immunohistochemistry. Patients with ependymoma or incomplete clinical records were excluded. Epidemiological variables, treatment modalities, tumoral and molecular characteristics were collected. Kaplan–Meier survival curves, log-rank tests, and Cox regression models were applied. Analyses were performed using SPSS 30.0. The study protocol was approved by the Bioethics Committee of The Panama Clinic (EC-CBITPC-063). RESULTS Among 196 patients, 59 (30%) were IDH-mutant and 137 (70%) IDH wild-type. Median OS was not reached for the IDH-mutant group but was 11.4 months (95% CI: 8.3–14.5) in the IDH wild-type group (p &amp;lt; 0.001). Median follow-up time was 34.23 months (95% CI: 25.9–42.5). A total of 123 patients (62.8%) died during follow-up. On multivariable analysis, age ≥ 65 years (HR 1.76; p = 0.008), biopsy-only procedure (HR 2.04; p = 0.004), and Karnofsky Index &amp;lt; 70% (HR 2.02; p = 0.010) predicted worse OS. IDH mutation (HR 0.25; p &amp;lt; 0.001) and frontal-lobe location (HR 0.61; p = 0.039) were associated with improved survival. CONCLUSION In this cohort, IDH mutation emerged as a strong independent predictor of OS. These findings support the routine implementation of IDH testing and expanded access to molecular diagnostics in glioma care across LMICs. Prospective studies are warranted to validate these results.

Previous studies investigated the impact of timing between neoadjuvant therapy (NAT) and radical cystectomy (RC) (NAT-to-RC interval) on overall survival (OS). However, these studies primarily focused on neoadjuvant chemotherapy (NAC), leaving the effects of neoadjuvant immunotherapy (NAI) and chemoimmunotherapy (NACI) unexplored. We retrospectively reviewed 717 treated with RC between 2015 and 2024 at a tertiary referral center. For the purpose of the study, patients receiving either NAC, NAI, or NACI were included. Multivariable Cox regression analysis (MCR) was used to assess the association between the NAT-to-RC interval and any cause of death. MCRs models together with the Harrell's C-index, were used to test progressively increasing weekly NAT-to-RC interval cut-offs. Kaplan-Meier analysis was used to estimate OS based on the first interval threshold significantly associated with survival outcomes. Among 246 eligible patients, 110 (45%) received NAC, 101 (41%) NAI, and 35 (14%) NACI. The NAT-to-RC interval was 46days (IQR: 28-71days). Over a median follow-up of 40months, 43 patients (17%) died from any cause. In MCR, longer NAT-to-RC intervals were significantly associated with reduced OS (per 2-week increase: Hazard ratio [HR] 1.06, p = 0.004). The first statistically significant cut-off was at 11weeks (adjusted HR: 1.88, p = 0.048, C-index: 74%). Patients with an interval of 11weeks or more (n = 53, 22%) had significantly lower 3-year OS than those with shorter intervals (86% vs. 75%, adjusted HR: 1.88, p = 0.048). Similar results were observed in the NAI/NACI subgroup with a 14-week cut-off (unadjusted HR: 4.27, p = 0.043, C-index: 59%). A prolonged NAT-to-RC interval is independently associated with poorer OS, even in patients receiving NAI or NACI. An interval of 11weeks is associated with a decline in OS, suggesting a potential time-sensitive impact of delayed RC. These findings underscore the importance of timely RC following NAT, particularly as the use of NAT strategies continues to expand.

Background: The prognosis and disease course of medullary thyroid carcinoma (MTC) can vary widely among patients. Effective risk stratification is important for ensuring timely treatment and personalized follow-up. Biomarkers can enhance risk stratification and guide the development of targeted anticancer therapies and imaging techniques. While numerous studies have explored various immunohistochemical biomarkers in MTC, an overview is still lacking. This study aimed to provide a comprehensive overview of immunohistochemical biomarkers and their role in the prognosis of MTC patients, with a primary focus on overall survival (OS). Methods: This review was preregistered in PROSPERO (CRD42023469437). A systematic search was performed using the online medical databases Embase, MEDLINE (Ovid), and Cochrane. Quality was assessed using an adapted scoring system based on the REMARK criteria and the Quality in Prognosis Studies tool. The primary outcome was OS. Secondary outcomes included other types of survival and associations with clinicopathological risk factors and recurrence. Results: Of 2992 studies, 108 were included, investigating 170 unique biomarkers and with sample sizes ranging from 11 to 327 participants. The majority (72%) were reported in only one article. A minority of studies were rated as high quality (28%). Markers of proliferation Ki-67 (Ki-67) and programmed cell death-ligand 1 (PD-L1) were significantly associated with OS (hazard ratio [HR]: 6.67, confidence interval [CI]: 1.43-31.18 and HR: 3.34, CI: 1.18-9.51). Conclusions: Our systematic review provides a comprehensive synthesis of the literature on immunohistochemical biomarkers in MTC and highlights the need for high-quality validation studies. Our meta-analysis confirms the prognostic value of Ki-67, although with varying certainty due to large differences in study quality. Furthermore, we describe the association of PD-L1 positivity with poorer OS, increased recurrence, and more aggressive clinicopathological features, which supports the rationale for further investigating the potential of anti-PD-1/PD-L1 immunotherapy for advanced MTC.

To apply a trial emulation method using the 'ENZAlutamide in first line androgen deprivation therapy for METastatic prostate cancer' (ENZAMET) trial data to assess the effects of adding early docetaxel to enzalutamide on overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC), as the benefits of adding early docetaxel to novel androgen-receptor pathway inhibitors (ARPIs) are unclear. The ENZAMET trial randomised 1125 patients with mHSPC to testosterone suppression plus enzalutamide or standard non-steroidal antiandrogen therapy. Investigators indicated at pre-randomisation if they planned to use early docetaxel. We emulated randomised comparisons of four treatments: (i) docetaxel plus enzalutamide, (ii) no docetaxel plus enzalutamide, (iii) docetaxel plus no enzalutamide, and (iv) no docetaxel plus no enzalutamide. Propensity score matching was applied to mitigate selection bias. OS was evaluated using Cox proportional hazards regression. Among 987 matched participants (87.7%), baseline characteristics were balanced. OS was similar with or without planned use of early docetaxel (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.92-1.12; P = 0.72), with effect modification by enzalutamide use (interaction P = 0.02). Among those assigned enzalutamide, OS was similar according to the planned use of early docetaxel or not (HR 1.18, 95% CI 0.94-1.49), regardless of disease volume (interaction P = 0.37). Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82-0.98), especially in high-volume disease (interaction P = 0.006). Early docetaxel did not appear to improve survival when added to enzalutamide, regardless of disease volume, whereas it did appear to improve survival when enzalutamide was not used, particularly in high-volume disease. While residual confounding could not be excluded, these findings do not support the routine addition of early docetaxel to enzalutamide in mHSPC.

Studies on mantle cell lymphoma (MCL) emphasize that patients with progression of disease (POD) ≤24 months have inferior prognosis compared to patients with later POD. This population-based study assessed the impact of POD on overall survival (OS) by timing of progression and first-line treatment. A total of 1186 MCL patients diagnosed 2006-2018 were identified in the Swedish lymphoma register. POD was defined as progressive disease after first-line treatment or relapse following initial response. Hazard ratios (HRs) with 95% confidence intervals (CIs), comparing all-cause mortality among patients with and without POD, were estimated with Cox regression. An illness-death model was used to quantify the impact of timing of progression on OS, conditional on the timepoint of POD/PF (progression-free). Patients were followed for up to 10 years following treatment (median 3.7 years). BR, Nordic MCL2, and R-CHOP/R-CHOP-like treatment were administered to 33%, 30%, and 14% of patients. Almost half (48%, n = 572) of patients experienced POD, with consequently higher mortality, regardless of timing and treatment (adjusted HR = 7.56, 95% CI: 6.32-9.05). Importantly, even for patients with POD after 6-10 years, mortality was more than two-fold increased (HR = 2.67, 95% CI: 1.05-6.79). On the absolute scale, a survival difference persisted for progression occurring up to 9 years after primary treatment. Especially early but also late progression (well beyond the 24-month mark) has a large negative impact on survival in MCL. These results highlight the need for improved first-line, including maintenance therapies to sustain remission and optimize outcomes for MCL patients.

Trends and efficacy of definitive radiotherapy regimens for locally advanced head and neck cancer in elderly patients: A population-based analysis by the German cancer registry group.

Comparative Efficacy and Safety of First-Line Treatment With Atezolizumab/Bevacizumab vs. Tyrosine-kinase Inhibitors in Patients With Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

The association of preneoadjuvant maximal standardized uptake value (SUVmax) and postneoadjuvant change in maximal standardized uptake value on 18-fluorodeoxyglucose positron emission tomography with survival after esophagectomy for cancer.

To investigate the impact of surgical resection and radiotherapy on overall survival (OS) in clinically distantly metastatic (cM1) major salivary gland cancer (MSGC). Retrospective cohort study. The 2006 to 2020 hospital-based National Cancer Database. The 2006 to 2020 National Cancer Database was queried for patients with cM1 MSGC undergoing chemotherapy. Kaplan-Meier and Cox proportional hazards regression models were implemented. Of 700 patients satisfying inclusion criteria, 219 (37.8%) underwent chemotherapy alone (ie, no local therapy), 159 (27.4%) underwent low-dose chemoradiotherapy (CRT), 56 (9.7%) underwent high-dose CRT, 47 (8.1%) underwent surgical resection + chemotherapy, 47 (8.1%) underwent surgical resection + low-dose CRT, and 52 (9.0%) underwent surgical resection + high-dose CRT; 5-year OS was 10%, 12%, 34%, 25%, 23%, and 28%, respectively (P < .001). Patients undergoing surgical resection underwent high-dose radiotherapy more frequently (N = 53, 36.1% vs N = 56, 12.9%) but multiple-agent chemotherapy less frequently (N = 105, 62.5% vs N = 363, 75.3%) than those not undergoing surgical resection (P < .005). Compared with chemotherapy alone, surgical resection + chemotherapy (aHR 0.67, 95% confidence interval [CI] 0.53-0.86), high-dose CRT (aHR 0.55, 95% CI 0.41-0.73), and immunotherapy (aHR 0.49, 95% CI 0.35-0.69) were associated with higher OS on multivariable Cox regression (P < .01). A minority of patients with cM1 MSGC underwent surgical resection or high-dose CRT. Despite the high rate of PSM, surgical resection was associated with higher OS than chemotherapy alone. High-dose CRT was associated with the highest OS. Definitive local therapy may benefit select patients with cM1 MSGC. IV.

Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data.

Prognostic impact of myopenia and establishment of a nomogram for predicting survival following radical gastrectomy in patients with gastric cancer: A multicenter study.